MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bone.2022.116416

Медицинская библиотека · Bone · 2022

Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.

Chiba Ko, Okazaki Narihiro, Kurogi Ayako, Watanabe Tsuyoshi, Mori Ai, Suzuki Nobuhiko, Adachi Koichi, Era Makoto, Yokota Kazuaki, Inoue Takuma, Yabe Yoshihiro, Furukawa Keizo, Kondo Choko, Tsuda Keiichi, Ota Shingo, Isobe Yusaku, Miyazaki Satsuki, Morimoto Shimpei, Sato Shuntaro, Nakashima Sawako, Tashiro Shigeki, Yonekura Akihiko, Tomita Masato, Osaki Makoto

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

PURPOSE: The effects of daily teriparatide (20 μg) (D-PTH), weekly high-dose teriparatide (56.5 μg) (W-PTH), or bisphosphonates (BPs) on areal bone mineral density (aBMD), bone turnover markers (BTMs), volumetric BMD (vBMD), microarchitecture, and estimated strength were investigated in postmenopausal osteoporosis patients.

METHODS

The study participants were 131 women with a history of fragility fractures. They were randomized to receive D-PTH, W-PTH, or BPs (alendronate or risedronate) for 18 months. Dual-energy X-ray absorptiometry (DXA), BTMs, and high-resolution peripheral quantitative CT (HR-pQCT) parameters were evaluated at baseline and after 6 and 18 months of treatment. The primary endpoint was the change (%) in cortical thickness (Ct.Th) after 18 months' treatment compared with baseline.

RESULTS

DXA showed that D-PTH, W-PTH, and BPs increased lumbar spine aBMD (+12.0%, +8.5%, and +6.8%) and total hip aBMD (+3.0%, +2.1%, and +3.0%), but D-PTH and W-PTH decreased 1/3 radius aBMD (-4.1%, -3.0%, -1.4%) after 18 months. On HR-pQCT, D-PTH increased trabecular vBMD (Tb.vBMD) at the distal radius and tibia after 18 months (+6.4%, +3.7%) compared with the BPs group, decreased cortical volumetric tissue mineral density (Ct.vTMD) (-1.8%, -0.9%) compared with the other groups, increased Ct.Th (+1.3%, +3.9%), and increased failure load (FL) (+4.7%, +4.4%). W-PTH increased Tb.vBMD (+5.3%, +1.9%), maintained Ct.vTMD (-0.7%, +0.2%) compared with D-PTH, increased Ct.Th (+0.6%, +3.6%), and increased FL (+4.9%, +4.5%). The BPs increased Tb.vBMD only in the radius (+2.0%, +0.2%), maintained Ct.vTMD (-0.6%, +0.3%), increased Ct.Th (+0.5%, +3.4%), and increased FL (+3.9%, +2.8%).

CONCLUSIONS

D-PTH and W-PTH comparably increased Ct.Th, the primary endpoint. D-PTH had a strong effect on trabecular bone. Although D-PTH decreased Ct.vTMD, it increased Ct.Th and total bone strength. W-PTH had a moderate effect on trabecular bone, maintained Ct.vTMD, and increased Ct.Th and total bone strength to the same extent as D-PTH.

Для цитирования: Chiba Ko, Okazaki Narihiro, Kurogi Ayako, Watanabe Tsuyoshi, Mori Ai, Suzuki Nobuhiko, Adachi Koichi, Era Makoto, Yokota Kazuaki, Inoue Takuma, Yabe Yoshihiro, Furukawa Keizo, Kondo Choko, Tsuda Keiichi, Ota Shingo, Isobe Yusaku, Miyazaki Satsuki, Morimoto Shimpei, Sato Shuntaro, Nakashima Sawako, Tashiro Shigeki, Yonekura Akihiko, Tomita Masato, Osaki Makoto. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.. Bone. 2022. DOI: 10.1016/j.bone.2022.116416.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.